Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 62
Posts 3,676
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
U.S. Stocks: S&P To Stick Above 2,000
U.S. stock futures pointed to soft gains on Wednesday, with the S&P 500 poised to stay above 2,000 a day after it closed above that milestone for the first time.
Top Equities Stories Of The Day
FTSE 100 Plays Catch-up With Europe, Climbs 0.7%
BofA Settlement Earmarks $7 Billion for Homeowners
American Man Fighting With Islamic State Is Killed in Syria
ArcelorMittal Climbs; Antofagasta Slides: European Movers
Salesforce, GameStop Lead Tech Stocks
ADR Shares End Lower; Vodafone Shares Active
ADR Shares End Higher; Statoil Shares Active
Miners Lift FTSE 100 For Second Straight Day
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 181497 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist